Stem Cell Therapy Market (2022-2029) Size Will Escalate Rapidly in the Near Future: Osiris Therapeutics, Molmed – Digital Journal

The Stem Cell Therapy Market research report forecast 2022 -2029 provides in-depth information on market trends, market capacity, industry size, growth factors, share, innovations, competitive environment, business problems, and more. This reports historical data confirms demand growth on a global, national, and regional scale. The research of the Stem Cell Therapy also aids in the understanding of industry prospects and growth chances. This report leverages advanced tools such as SWOT analysis and Porters Five Forces analysis to accurately estimate market and revenue growth. The report also provides an extensive analysis of the impact of the COVID-19 pandemic and how it contributed to market progress.

Market research reports from WMR include a competitive landscape, in-depth vendor selection methodology, and analysis based on qualitative and quantitative research to properly Stem Cell Therapy Market growth. In this Research Report, by analyzing key aspects such as profit, pricing, competition, and promotions, as well as examining, synthesizing, and summarising data from many sources, the analyst produces a comprehensive picture of the Stem Cell Therapy market. It shows a variety of market elements by identifying the top industry influencers. The market study further also draws attention to crucial industry factors such as global clients, potential customers, and sellers, which instigates positive company growth. In order to gauge the turning point of the businesses, significant market key players are also enlisted in order to deliver readers an in-depth analysis of industry strategies.

Osiris Therapeutics Molmed JCR Pharmaceutical NuVasive Anterogen Chiesi Pharmaceuticals Medi-post Pharmicell Takeda (TiGenix)

% :https://www.worldwidemarketreports.com/promobuy/839327

:

Global markets are presented by Stem Cell Therapy type, along with growthforecasts. Estimates of production and valueare based on the price in the supply chain at which the Stem Cell Therapy are procured by the manufacturers.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows production and revenue data by type, and during the historical period and forecast period.

Autologous Allogeneic

:

This report has provided themarket size (production and revenue data) by application, during the historical period and forecast period.

This report also outlines the market trends of each segment and consumer behaviors impacting the Stem Cell Therapy market and what implications these may have on the industrys future. This report can help to understand the relevant market and consumer trends that are driving the Stem Cell Therapy market.

Musculoskeletal Disorder Wounds & Injuries Cornea Cardiovascular Diseases Others

:

The Stem Cell Therapy Market engineering process uses a top-down and bottom-up approach and several data triangulation methods to evaluate and validate the size of the entire market and other dependent sub-markets listed in this research report. The major players in the market were identified through the second survey and the market rankings were determined through the first and second surveys.

To analyze actual Stem Cell Therapy market sales and their breakdowns, primary and secondary approaches were used. The Stem Cell Therapy assessment comprised extensive primary searches, such as surveys, expert opinions, profiles, and secondary ratings to business magazines, industry directories, paid venues, and others. In addition, the industry research examines data acquired from a range of sector analysts and significant market participants along the industrys value chain to provide a succinct quantitative and qualitative analysis.

:

:

North America (U.S., Canada, Mexico) Europe (U.K., Italy, Germany, France, Rest of the EU) Asia-Pacific (India, Japan, China, South Korea, Australia, Rest of APAC) Latin America (Chile, Brazil, Argentina, Rest of Latin America) Africa and the Middle East (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

?

This research contains detailed information on the factors that are projected to impact Stem Cell Therapy market growth and share in the future.

The report examines the present situation of the Stem Cell Therapy market as well as future prospects for a variety of geographic locations.

It can be used as a SWOT and competitive landscape study when combined with Porters Five Forces analysis.

It gives an in-depth examination of the industry, highlighting its growth rates and expansion potential.

The research contains a wealth of information, including Stem Cell Therapy market dynamics and opportunities for the forecast period.

Quantitative, qualitative, value (USD Million), and volume (Units Million) data are among the segments and sub-segments.

Data on demand and supply forces, as well as their impact on the Stem Cell Therapy market, may be found at the regional, sub-regional, and country levels.

% :https://www.worldwidemarketreports.com/promobuy/839327

!

:

Mr. ShahWorldwide Market Reports, Tel: U.S. +1-415-871-0703 U.K. +44-203-289-4040 Japan +81-50-5539-1737 Email: [emailprotected] Website:https://www.worldwidemarketreports.com/

Visit link:
Stem Cell Therapy Market (2022-2029) Size Will Escalate Rapidly in the Near Future: Osiris Therapeutics, Molmed - Digital Journal

Global Cell Therapy Market Report (2022 to 2028) – Featuring Thermo Fisher Scientific, MaxCyte, Danaher and Avantor Among Others -…

DUBLIN--(BUSINESS WIRE)--The "Global Cell Therapy Market, By Use Type, By Therapy Type, By Product, By Technology & By Region- Forecast and Analysis 2022-2028" report has been added to ResearchAndMarkets.com's offering.

The Global Cell Therapy Market was valued at USD 14.86 Billion in 2021, and it is expected to reach a value of USD 35.95 Billion by 2028, at a CAGR of 13.45% over the forecast period (2022 - 2028).

Companies Mentioned

The cell therapy industry is being propelled forward by an increase in the number of clinical trials for cell-based treatments. As a result, global investment in research and clinical translation has increased significantly. The increasing number of ongoing clinical studies can be attributed to the presence of government and commercial funding bodies that are constantly providing funds to assist projects at various stages of clinical trials.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research and their market shares in the respective regions were determined through primary and secondary research.

This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives.

All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report

The global cell therapy market is segmented based on Use-type, Therapy Type, Product, Technology, Application, and Region. Based on Use-type it is categorized into Clinical-use, and Research-use. Based on Therapy Type it is categorized into Allogenic Therapies, Autologous Therapies.

Based on Product it is categorized into Consumables, Equipment, Systems, and Software. Based on Technology it is categorized into Viral Vector Technology, Genome Editing Technology, Somatic Cell Technology, Cell Immortalization Technology, Cell Plasticity Technology, and Three-Dimensional Technology. Based on the region it is categorized into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers

The increased demand for novel, better medicines for diseases such as cancer and CVD has resulted in an increase in general research efforts as well as funding for cell-based research. In November 2019, the Australian government released The Stem Cell Therapies Mission, a 10-year strategy for stem cell research in Australia.

The project would receive a USD 102 million (AU$150 million) grant from the Medical Research Future Fund (MRFF) to encourage stem cell research in order to develop novel medicines. Similarly, the UK's innovation agency, Innovate the UK, awarded USD 269,670 (GBP 267,000) in funding in September 2019 to Atelerix's gel stabilization technologies, with the first goal of extending the shelf-life of Rexgenero's cell-based therapies for storage and transport at room temperature.

Restraints

Despite technological advancements and product development over the last decade, the industry has been hampered by a lack of skilled personnel to operate complex devices like flow cytometers and multi-mode readers. Flow cytometers and spectrophotometers, which are both technologically advanced and extremely complex, generate a wide range of data outputs that require skill to analyze and review.

There is a global demand-supply mismatch for competent individuals, according to the National Accrediting Agency for Clinical Laboratory Sciences (NAACLS). Over the next decade, the UK and Europe are expected to face a severe shortage of lab capabilities, with medical laboratories being particularly hard hit.

Market Trends

The expansion of the cell therapy market was aided by the growing frequency of chronic illnesses. Chronic illness is defined as a condition that lasts one year or more and requires medical treatment, affects everyday activities, or both, according to the US Centers for Disease Control and Prevention (CDC).

It includes heart disease, cancer, diabetes, and Parkinson's disease. Patients with spinal cord injuries, type 1 diabetes, Parkinson's disease (PD), heart disease, cancer, and osteoarthritis may benefit from stem cells.

For more information about this report visit https://www.researchandmarkets.com/r/aqmxta

Read this article:
Global Cell Therapy Market Report (2022 to 2028) - Featuring Thermo Fisher Scientific, MaxCyte, Danaher and Avantor Among Others -...

A CRISPR Alternative for Correcting Mutations That Sensitize Cells to DNA Damage – The Scientist

Fanconi anemia is a rare genetic disease in which essential DNA repair pathway genes are mutated, disrupting the DNA damage response. Patients with Fanconi anemia experience hematological complications, including bone marrow failure, and are predisposed to cancer. The only curative therapy for the hematological symptoms of Fanconi anemia is an allogeneic hematopoietic stem cell transplant, in which a patient receives healthy stem cells from a donor. While this may cure or prevent some of the diseases complications, stem cell transplantation can cause additional difficulties, including graft-versus-host disease (GvHD) and exacerbated cancer risk.1

There is growing interest in applying genome editing technologies like CRISPR-Cas9 to correct Fanconi anemia mutations in patient-derived cells for autologous transplants, in which corrected stem cells are given back to the patient. However, this disease poses a unique challenge: How do you apply a genome editing technique in cells that are particularly sensitive to DNA damage? Fanconi anemia cells cannot resolve the double-strand breaks that conventional CRISPR-Cas9 gene editing creates in the target DNA, which prevents researchers from effectively correcting disease-causing mutations with this method.

In a study published in International Journal of Molecular Science, a research team at the University of Minnesota led by Branden Moriarity and Beau Webber used Cas9-based tools called base editors (BEs) to edit genes in Fanconi anemia patient-derived cells without inducing double-strand DNA damage.2 BEs are fusion proteins made of a Cas9 enzyme that cleaves target DNA (nCas9) and a deaminase that converts cytidine to uridine (cytosine base editor, CBE) or adenosine to inosine (adenosine base editor, ABE). During DNA replication or repair, sites targeted by a BE are rewritten as thymine in the case of CBEs, or guanine with ABEs.

Although base editors do not induce double-strand breaks, they still nick the DNA and trigger a DNA repair response. Because of this, the researchers first examined if CBEs and ABEs would work on non-Fanconi anemia genes in patient-derived cells. There was that mystery, you know, because [Fanconi anemia patient cells are] DNA repair deficient. So we weren't surewe thought maybe it would work, but not as well as a normal cell. But indeed, it works on the same level, basically. So that was pretty exciting, Moriarity explained.

The research team then demonstrated that CBEs and ABEs can correct Fanconi anemia-causing mutations in the FANCA gene in primary patient fibroblast and lymphoblastoid cell lines. Base editing restored FANCA protein expression and improved the ability of the patient-derived cells to grow in the presence of a DNA damaging chemical. Additionally, in culture, fibroblasts with corrected FANCA mutations outgrew cells in which the base editing failed. Finally, the researchers assessed if BEs could correct mutations in different Fanconi anemia genes. Using an algorithm, they predicted that most Fanconi anemia mutations were correctable either by BEs or by another nCas9-fusion technology called prime editing (PE), which is capable of large genetic insertions and deletions.

This work comes on the heels of a preprint from another research group at The Centre for Energy, Environmental and Technological Research and ETH Zurich, who investigated ABEs in patient blood cell lines. This group also effectively targeted Fanconi anemia genes with BE technology, and their investigation went one step further: they corrected mutations in patient-derived hematopoietic stem cells.3This was something that Moriarity and Webber were unable to dobecause the disease is a bone marrow failure syndrome, these cells are scarce. Basically, these patients do not have stem cells, explains Annarita Miccio, a senior researcher and lab director at Institute Imagine of Paris Cit University, who was not involved in either study. These are very challenging experiments, and more than the experiments, the challenge of [treating] Fanconi anemia is exactly thatthe number of cells.

Despite this challenge, the researchers have laid the groundwork for genome editing as a treatment approach in Fanconi anemia, without the need for double-strand DNA breaks. I think the study we did is a good, solid proof of concept, and sets the stage for the next steps, but certainly, it's not the end of the story, said Webber.

References

Follow this link:
A CRISPR Alternative for Correcting Mutations That Sensitize Cells to DNA Damage - The Scientist

Fighting One Disease or Condition per Day – Daily Kos

When I was young,,,

36 reasons to VOTE YES! For Your Scientist Friends

By Don C. Reed

Author, STEM CELL BATTLES, other books

http://www.stemcellbattles.com

Dear Friend of Regenerative Medicine:

For the next month, I will make available a daily summary of one aspect of stem cell researchmy laymans understanding of itdone by scientists connected to the California Institute for Regenerative Medicine (CIRM). Todays is spina bifida, tomorrow is stroke.

Mistakes are mine.

In most cases I have left out the scientists names. A few I have written about in my books, and those I felt free to credit.

All I ask is that when you step into the voting booth, please consider which political party is likely to fund such research, and vote accordingly.

Spina Bifida: total awards (3) Award value: $16,798,263

The condition is devastating, and lasts a lifetime. The baby has a part of its spine bulging out of its lower back. Accompanying symptoms are many, including: headaches, vomiting, weakness in the legs, bladder and bowel problems.

Current standard of care (in utero surgery) leaves 58% of patients unable to walk independently.

39% of affected population are Hispanic or Latino descent.

The condition may cost several million dollars per patient, over his or her lifetime.

Spina Bifida (SB) appears to be caused by a combination of genetic and environmental conditions, but no one is sure. How will CIRM fight such a thing?

One way is Placenta-derived mesenchymal stem cells, seeded on a Cook Biodesign extracellular Matrix. Think of a mesh screen, over the wound.

THERAPEUTIC MECHANISM: Mesenchymal stem cellssecrete growth factors (and) cytokinesprotecting motor neurons from cell deathtreatment increases the density of motor neurons in the spinal cord, leading to improved motor functionultimately reducing lower limb paralysis. (1)

Grant recipient Diana Farmer began science as a marine biologist, who doing research at the famous Woods Hole Institute. On the way to receive an award, she suffered a car accident, and changed her mind, working on human biology. She was the first woman to perform surgery on a baby in its mothers womb. (1)

She and Aijun Wang received a CIRM grant to co-launch the worlds first human clinical trial using stem cells to treat spina bifida.. (2)

1. https://en.wikipedia.org/wiki/Diana_L._Farmer

2. https://health.ucdavis.edu/health-news/newsroom/state-stem-cell-agency-funds-clinical-trial-for-spina-bifida-treatment/2020/11

Read the rest here:
Fighting One Disease or Condition per Day - Daily Kos

Stem Cell Cartilage Regeneration Market Size to Grow At A CAGR Of 9.1 % During 2022 To 2030 | Anika Therapeutics, Zimmer Biomet, BioTissue…

Stem Cell Cartilage Regeneration market report provides a detailed study of global market scope, regional and country-level market size, segmentation, growth, share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches and technological innovations.

In cartilage regeneration, stem cells have the potential for multiple differentiation and self-replication, making it an ideal choice for use as seed cells. Growing regenerative medicine industry and increasing demand for stem cells in the development of various types of cell therapies are expected to drive growth of the market over the forecast period. Mesenchymal stem cells are the most widely applied stem cells in the field of cartilage regeneration.

Market segmentationStem Cell Cartilage Regeneration market is divided by Type and Application. For the period 2022-2030, the growth among segments provides accurate calculations and forecasts for revenue by Type and Application. This analysis can help you expand your business by targeting qualified place market

Click Here to Request a sample copy: https://www.marketresearchinc.com/request-sample.php?id=14444

Market segment by Type, covers

Market segment by Application, can be divided into

Market segment by players, this report covers

Anika Therapeutics, Zimmer Biomet, BioTissue Technologies, DePuy (Johnson& Johnson), Genzyme, CellGenix

Market segment by regions, regional analysis covers

Click Here to Purchase This Report: https://www.marketresearchinc.com/ask-for-discount.php?id=14444

Years Considered for the Stem Cell Cartilage Regeneration Market Size:

Reasons to Purchase the Stem Cell Cartilage Regeneration Market Report:

The report covers exhaustive analysis on:

For Any Enquiries/Customization Related [emailprotected] https://www.marketresearchinc.com/enquiry-before-buying.php?id=14444

Contact Us

Market Research Inc

Author:Kevin

US Address:51 Yerba Buena Lane, Ground Suite,

Inner Sunset San Francisco, CA 94103, USA

Call Us:+1 (628) 225-1818

Write Us:[emailprotected]

Read this article:
Stem Cell Cartilage Regeneration Market Size to Grow At A CAGR Of 9.1 % During 2022 To 2030 | Anika Therapeutics, Zimmer Biomet, BioTissue...

American Academy of Stem Cell Physicians to Offer Licensed Physicians Board Examination in Regenerative Medicine – BioSpace

MIAMI, Oct. 11, 2022 (GLOBE NEWSWIRE) -- The American Academy of Stem Cell Physicians will be hosting its fall Scientific Congress in Chicago, IL, on Oct. 28-30, 2022. The conference will feature three days of educational and networking events with leading physicians from across the fields of stem cells, live cells, and regenerative medicine. A Board Examination process will be available, creating a pathway for participants to earn a Diplomat and Fellowship Certification in Regenerative Medicine.

The Board of American Academy of Stem Cell Physicians is the official board certifying body of the American Academy of Stem Cell Physicians (AASCP). As a nationally recognized academy with a mission to bring like-minded physicians together to increase awareness and education for the evolving field of regenerative medicine, the AASCP is proud to announce its Fellowship and Diplomat Certification.

In order to be eligible for certification or recertification through the AASCP, licensed physicians in good standing must meet the stringent eligibility requirements that have been defined by the board. AASCP places an emphasis on not only psychometrically evaluated testing and advanced training, but also moral character and experience. Furthermore, AASCP has a clear path toward recertification for qualified physicians. Their standards for recertification include a commitment to continuing medical education, successful completion of a recertification examination, participation in a non-remedial medical ethics program, and additional requirements.

AASCP is known for working with physicians to provide unique opportunities for board certification in their specialty of regenerative medicine. Specifically, the AASCP offers ongoing workshop modules led by esteemed physicians in this field who certify and educate on different treatment approaches and techniques. Another defining characteristic of the AASCP is their commitment to ongoing education and awareness. To support this goal, the AASCP has developed innovative committees, including its Institutional Review Board and created opportunities for physicians and researchers to submit their work for peer review and exposure.

The AASCP was founded to recognize licensed physicians who have shown a specialty and interest in regenerative medicine. Increasingly, hospitals and medical staff placement agencies are prioritizing hiring Board-Certified Physicians. For this reason, the AASCP feels it is important to offer qualified professionals a choice when they're researching board certifying bodies.

The American Academy of Stem Cell Physicians (AASCP) is an organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatment and prevention of disease related to or occurring within the human body. Secondarily, the AASCP aims to serve as an educational resource for physicians, scientists and the public in diseases that can be caused by physiological dysfunction that are ameliorable to medical treatment.

For further information, please contact Wilson Demenessez at 305-891-4686, and you can also visit us at http://www.aascp.net.

Contact Information: Wislon Demenessezz AASCP account Sales manager wilson@genorthix.com 305-891-4686

Related Images

Image 1: AASCP Chicago lecture

Meeting lecture

This content was issued through the press release distribution service at Newswire.com.

Attachment

Visit link:
American Academy of Stem Cell Physicians to Offer Licensed Physicians Board Examination in Regenerative Medicine - BioSpace

Nine postdoctoral fellowships in aging research awarded by the Glenn Foundation for Medical Research and AFAR – EurekAlert

Announcing the 2022 Glenn Foundation for Medical Research Postdoctoral Fellowships in Aging Research Recipients

NEW YORK, NY and SANTA BARBARA, CA The American Federation for Aging Research (AFAR) and the Glenn Foundation for Medical Research are pleased to announce the recipients of the2022 Glenn Foundation for Medical Research Postdoctoral FellowshipsinAgingResearch.Thisprogramsupportspostdoctoralfellowswhostudybasicresearchmechanisms of aging and/or translational findings that have potential to directly benefit human health.

Selected through a rigorous review process,nine,one-year,$60,000Postdoctoral Fellowshipshavebeenawarded this year to advance research on a range of topics in the biology of aging, geroscience, and potential therapeutics:

"The fellowships significant research and training support to permit postdoctoral fellows to develop skills and competencies needed to become established in the field of aging, " notes Stephanie Lederman, EdM, Executive Director of AFAR. "With this recognition, and the ability to develop an independent research project, they are more competitive when vying for coveted junior faculty positions and when applying for larger grant support."

Theseawardsprovidepostdoctoralfellowstheopportunitytodevelopindependentresearchprojects, notes Mark R. Collins, President of the Glenn Foundation for Medical Research. Their findings today will help deepen knowledge, foster collaborations, and further therapeutic interventions tomorrow.

Learn more about this grant programhereand the 2022 recipientshere.

###

About the Glenn Foundation for Medical Research- Founded by Paul F. Glenn in 1965, the mission of the Glenn Foundation for MedicalResearchistoextendthehealthyyearsoflifethroughresearchonmechanismsofbiologythatgovernnormalhumanaging and its related physiological decline, with the objective of translating research into interventions that will extend healthspan with lifespan. Learn more atglennfoundation.org.

AboutAFAR-The American Federation for Aging Research (AFAR) is a national non-profit organization that supports and advances pioneering biomedical research that is revolutionizing how we live healthier and longer. For more than four decades, AFAR has served as the fields talent incubator, providing more than $193 million to nearly 4350 investigators at premier research institutions to dateand growing. In 2022, AFAR is expected to award over $11,000,000 to more than 60 investigators. A trusted leader and strategist, AFAR also works with public and private funders to steer high quality grant programs and interdisciplinary research networks. AFAR-funded researchers are finding that modifying basic cellular processes can delayor even preventmany chronic diseases, often at the same time. They are discovering that it is never too lateor too earlyto improve health. This groundbreaking science is paving the way for innovative new therapies that promise to improve and extend our quality of lifeat any age. Learn more atwww.afar.orgor follow AFARorg on Twitter and Facebook and American Federation for Aging Research on LinkedIn.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Continue reading here:
Nine postdoctoral fellowships in aging research awarded by the Glenn Foundation for Medical Research and AFAR - EurekAlert

The Issue of Tissue: Getting to the Source of the HIV Reservoir – amfAR, The Foundation for AIDS Research

Not all stem cell transplants in individuals living with HIV and cancer, such as those used to cure Timothy Ray Brown and Adam Castillejo, among others, have been successful. Yet much can be learned about curing HIV from those whose lives could not be saved.

Research question Currently the only curative intervention for HIV is to transplant donor cells with a CCR5 delta32 genetic mutation in a person living with HIV (PLWH). But the impact of such transplants on HIV reservoirs in various organs has not been extensively characterized. A consortium of European researchers known as IciStem, established through amfAR funding, sought to gauge this impact by studying autopsy specimens from two individuals who underwent such transplants but were not cured and died soon afterwards.

Findings The first individual had been infected with HIV for 14 years and treated with antiretroviral therapy (ART) for that entire period. He was given a transplant in an attempt to cure a blood disorder known as MDS. On the 36th day following that procedure he achieved 100% chimerism. That meant that all his newly formed immune and other blood cells were the offspring of the donor and should be resistant to HIV infection. However, 29 days later that 100% value fell to 85%presumably related to an initially undetected population of recipient cells that were not destroyed by the transplant preparation procedure. He died of severe sepsis. At that time his blood still had no evidence of HIV, but all organs sampled, from brain to lymph node, showed signs of persistent infection.

The second individual had been infected with HIV for 22 years and treated with ART for the last 19 years. He required two transplants in an attempt to cure his acute leukemiathe first one having failed to take holdand on the 100th day following the first transplant (29 days after the second procedure) he achieved 100% chimerism. However, he died of lung failure eight days later. At that time no virus could be found in the blood, but the lymph node and spleen showed persistence of an HIV reservoir.

Impact The authors emphasize the need for examining tissues, not just blood, of PLWH having undergone potentially curative interventions as their results document that [t]issues play an essential role as a long-standing viral reservoir and routine [blood] sampling in living HIV-1-individuals will be insufficient to represent the extent of this reservoir.

amfARs role amfAR was a funder of this research.

Original article http://www.ncbi.nlm.nih.gov/pubmed/36146874

Dr. Laurence is amfARs senior scientific consultant.

See more here:
The Issue of Tissue: Getting to the Source of the HIV Reservoir - amfAR, The Foundation for AIDS Research

Sysmex : and JCR Pharmaceuticals Establish a Joint Venture in the Field of Regenerative Medicine and Cell Therapy- Aiming for the Research &…

In recent years, the significant potential of regenerative medicine and cell therapy have been established in particular in areas that have traditionally been difficult to address with conventional chemically synthesized low molecular weight drugs1 or biopharmaceuticals,2 such as the restoration of tissues and functions lost as a result of aging, illness, autoimmune diseases, or cancer. In particular, research and development on the therapeutic application of stem cells including hematopoietic stem cells, mesenchymal stem cells, and iPS cells have generated significant attention.

Since its foundation, Sysmex has provided network solutions using IoT (Internet of Things) and automated testing flows to improve the safety of healthcare professionals and for the optimization of operational efficiency in clinical laboratories. In addition, while providing quality control testing for companies which develop regenerative medicine products, Sysmex has conducted research and development related to new pre-transplant compatibility testing examining the patient's immune response against the organ or tissue to be transplanted.

Since its inception, JCR has been engaged in the research, development, manufacturing and sales of pharmaceutical products using regenerative medicine, genetic engineering, and gene therapy technologies to advance therapies in the rare disease field. This is exemplified in the field of regenerative medicine, by the approval of TEMCELL HS Inj.,3 the first allogeneic regenerative medicine in Japan (Non-proprietary name: Human (allogeneic) bone marrow-derived mesenchymal stem cells) in February 2016 for the treatment of acute graft-versus-host disease (acute GVHD),4 a serious complication that develops after hematopoietic stem cell transplantation. In recent years, JCR has further streamlined and integrated its expertise around the establishment of groundbreaking medicines for the advancement of highly innovative medicines that could not be developed without such groundbreaking technologies.

In the joint venture, the two companies aim to realize the social implementation of regenerative medicine and cell therapy by integrating Sysmex's expertise in quality control testing technology and knowledge of workflows efficiency using robotics technology, including IoT, with JCR's expertise in developing, manufacturing and marketing regenerative medicine products. AlliedCel Corporation, which is the corporate name of the joint venture following prior discussions regarding the alliance both companies, was established on October 3, 2022. The joint venture will advance programs of the potential for technology development and commercialization, including the project currently being promoted by both companies using hematopoietic stem cell proliferation technology.

The name AlliedCel stands for the joint venture's aspiration to integrate knowledge and expertise from a broad set of collaborators and stakeholders including business partners, patients and their families, with the united goal of unleashing the power of cells in supporting patients in their need for life-changing therapies. Through the research and development of regenerative medicine products using diverse cells such as stem cells, AlliedCel aims to provide appropriate treatment options to patients and improve their prognosis.

Profile of the Joint Venture

Capital reserve:

100 million JPY

President: Hiroyuki Sonoda

(Vice President, Research and Corporate Strategy, Executive Director of Research Division, JCR Pharmaceuticals Co., Ltd.)

Executive Vice President, Member of the Managing Board: Kenji Tsujimoto

(Executive Vice President of Technology Strategy Division, Sysmex Corporation)

About Sysmex Corporation

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values - reliability, confidence, and persistence - benefit all our stakeholders, including employees, partners, and patients. Together we soar.

Disclaimer

Sysmex Corporation published this content on 03 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 October 2022 06:13:01 UTC.

Publicnow 2022

Technical analysis trends SYSMEX CORPORATION

Income Statement Evolution

See original here:
Sysmex : and JCR Pharmaceuticals Establish a Joint Venture in the Field of Regenerative Medicine and Cell Therapy- Aiming for the Research &...

The Importance of Growth Factor Quality in Organoid Cultures – The Scientist

Within a decade from their first demonstration, organoids have become a quintessential tool for fundamental and biomedical research, serving as relevant models for studying human development and disease.1 Animal and classical 2D cell culture models dominated biological research during the late twentieth and early twenty-first centuries. While these models offer unique advantages for understanding cellular signaling pathways, drug action mechanisms, and disease pathologies, one system alone cannot address them all. Therefore, researchers use various systems at different stages of basic and translational research. However, assessing information from different models slows down discovery for human clinical applications.2

Further, several biological phenomena that are specific to humans do not occur in animal models. For example, several human brain cell types are not found in the rodent brain. Also, the human brains neurodevelopmental mechanisms are far more complex compared to those in rodent brains. Moreover, human brain cell physiology differs when grown in 2D cell cultures and cannot reliably predict drug responses at preclinical stages. So far, human 3D organoids are the only system poised to overcome these limitations.

Organoids are small, self-organized 3D tissue cultures derived from adult stem cells, pluripotent stem cells, or primary tissues. They offer a huge advantage over 2D cell cultures by replicating in vivo organ complexity and tissue architecture. Analyzing organoid formation and function provides valuable information about human development, tissue formation, and organ function as well as a direct tool for pharmaceutical drug testing.

Organoid culture overview

Sino Biological

Researchers generate organoid cultures using multipotent or pluripotent stem cells in a 3D matrix, such as Matrigel, under self-organization promoting conditions. The composition of the growth medium is critical for the health and success of organoid cultures, and is typically enhanced with essential growth factors, such asepidermal growth factor (EGF),noggin (NOG), R-spondin (RSPO1),human growth factor (HGF), bone morphogenetic proteins (BMP), andfibroblast growth factor (FGF). These growth factors activate critical signaling pathways in the organoids to drive development or differentiation. Each culture type requires a distinct set of growth factors. For example, human colon organoids require EGF, NOG, and RSPO1 factors for differentiation, whereas human liver organoids need EGF, NOG, FGF10, and BMP7 for differentiation.2

Manufacturers produce these growth factors in eukaryotic expression systems to obtain structurally and functionally viable products. However, this process creates impurities, including secreted proteins and growth factors from the expression cells and their culture medium, affecting organoid survival and growth. Moreover, different cell lines create batch-to-batch variability in growth factor activity, influencing accuracy and reproducibility in organoid cultures.2

Sino Biological developed a host of recombinant growth factors necessary for organoid culture, including human EGF, NOG, RSPO1, and HGF among many others. These pure factors show high bioactivity, minimal endotoxin contamination, and batch-to-batch consistency, enabling optimal and consistent organoid growth.2 For example, using gel electrophoresis and high-performance liquid chromatography, the manufacturer determined the human EGF purity to be more than 95 percent. The activity of the recombinant human EGF was demonstrated by a cell proliferation assay using BALB/c 3T3 mouse embryonic fibroblasts, and the ED50 for this effect was typically 0.02-0.2 ng/mL. In addition, the purified growth factors are proven to promote or inhibit key pathways for proper stem cell development at low concentrations.2

Overall, Sino Biologicals purified growth factors effectively supplement organoid cultures, allowing them to be a trustworthy tool for researchers working to understand human development and disease.

References

See original here:
The Importance of Growth Factor Quality in Organoid Cultures - The Scientist